
Please try another search
Breaking News
For the three months ended 31 March 2022, Vaxcyte Inc revenues was not reported. Net loss increased 84% to $39M. Higher net loss reflects Research and development increase of 43% to $23.7M (expense), Foreign Exchange Gain/LossNon-Business decrease of 100% to $6K (income), Stock-based Compensation in SGA increase of 97% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.41 to -$0.68.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -39.22 | -29.85 | -26.95 | -23.73 |
Net Income | -38.99 | -28.56 | -26.61 | -23.68 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 402.72 | 324.34 | 354.07 | 358.05 |
Total Liabilities | 43.17 | 40.32 | 48.11 | 41.03 |
Total Equity | 359.54 | 284.02 | 305.96 | 317.02 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -27.7 | -121.39 | -70.3 | -41.88 |
Cash From Investing Activities | 49.67 | -212.31 | -212.39 | -193.92 |
Cash From Financing Activities | 111.02 | 17.8 | 9.04 | 1.44 |
Net Change in Cash | 132.76 | -316.34 | -273.29 | -234.33 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review